Business Description
Mineralys Therapeutics is a U.S.-based drug development company focused on conditions caused by the body producing too much of the hormone aldosterone, which plays a key role in regulating blood pressure and kidney function. Its lead drug candidate, lorundrostat, is a pill designed to block the enzyme responsible for aldosterone production and is being studied as a potential treatment for high blood pressure, chronic kidney disease, and sleep apnea. Founded in 2019 and based in Radnor, Pennsylvania, the company operates under a name it adopted in 2020.
